LGALS3 and central nervous system cancer: Using both in vitro and in vivo models, Ikemori and colleagues [70] showed, for example, that Gal-3 knockdown in human U87MG cells delayed tumor engraftment and reduced tumor growth, providing support for the possibility of targeting Gal-3 to sensitize glioma cells to cell death.